Correlation of Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and Retinoid X Receptor-α (RXR-α) expression with clinical risk factors in patients with advanced carotid atherosclerosis

被引:26
|
作者
Giaginis, Constantinos [2 ]
Klonaris, Christos [3 ]
Katsargyris, Athanasios [3 ]
Kouraklis, Gregorios [2 ]
Spiliopoulou, Chara
Theocharis, Stamatios [1 ]
机构
[1] Univ Athens, Sch Med, Dept Forens Med & Toxicol, GR-11527 Athens, Greece
[2] Univ Athens, Sch Med, Dept Propedeut Surg 2, GR-11527 Athens, Greece
[3] Univ Athens, Sch Med, Dept Surg 1, GR-11527 Athens, Greece
来源
MEDICAL SCIENCE MONITOR | 2011年 / 17卷 / 07期
关键词
carotid atherosclerosis; immunohistochemistry; macrophages; PPAR-gamma; RXR-alpha; smooth muscle cells; E-KNOCKOUT MICE; INHIBITS ATHEROSCLEROSIS; THERAPEUTIC TARGET; GENE-EXPRESSION; LIGANDS; DIFFERENTIATION; INFLAMMATION; STENOSIS; PATHWAY; ENDARTERECTOMY;
D O I
10.12659/MSM.881849
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its nuclear partners, the Retinoid X Receptors (RXRs), have been recognized as crucial players in the pathogenesis of atherosclerosis. The present study aimed to assess the clinical significance of PPAR-gamma and RXR-alpha expression in different cellular populations localized within advanced carotid atherosclerosis lesions. Material/Methods: PPAR-gamma and RXR-alpha expression was assessed by immunohistochemistry in 134 carotid atherosclerotic plaques obtained from an equal number of patients that underwent endarterectomy procedure for vascular repair, and was correlated with patients' medical history, risk factors and medication intake. Results: Increased incidence of low PPAR-g expression in both macrophages and smooth muscle cells was noted in patients presenting coronary artery disease (p=0.032 and p=0.046, respectively). PPAR-gamma expression in smooth muscle cells was borderline down-regulated in symptomatic compared to asymptomatic patients (p=0.061), reaching statistical significance when analyzing groups of patients with specific cerebrovascular events; amaurosis fugax (p=0.008), amaurosis fugax/stroke (p=0.020) or amaurosis fugax/transient ischemic attack patients (p=0.028) compared to asymptomatic patients. Low RXR-alpha expression in macrophages was more frequently observed in hypertensive (p=0.048) and hyperlipidemic patients (p=0.049). Increased incidence of low RXR-alpha expression in smooth muscle cells was also noted in patients presenting advanced carotid stenosis grade (p=0.015). Conclusions: PPAR-gamma and RXR-alpha expression down-regulation in macrophages and smooth muscle cells was associated with a more pronounced disease progression in patients with advanced carotid atherosclerotic lesions.
引用
收藏
页码:CR381 / CR391
页数:11
相关论文
共 50 条
  • [21] Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Activation Confers Functional Neuroprotection in Global Ischemia
    Zahra Fatehi-Hassanabad
    R. A. Tasker
    Neurotoxicity Research, 2011, 19 : 462 - 471
  • [22] INHIBITION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-α (PPAR-α) REDUCES PROLIFERATION OF PRENEOPLASTIC LIVER FOCI
    Casella, M. L.
    Monti, J. A.
    Parody, J. P.
    Ceballos, M. P.
    Ingaramo, P. I.
    Frances, D. E.
    Ronco, M. T.
    Pisani, G. B.
    Carnovale, C. E.
    Carrillo, M. C.
    Alvarez, M. L.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S106 - S106
  • [23] Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Activation Confers Functional Neuroprotection in Global Ischemia
    Fatehi-Hassanabad, Zahra
    Tasker, R. A.
    NEUROTOXICITY RESEARCH, 2011, 19 (03) : 462 - 471
  • [24] Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands as potential therapeutic agents to treat arthritis
    Giaginis, Costas
    Giagini, Athina
    Theocharis, Stamatios
    PHARMACOLOGICAL RESEARCH, 2009, 60 (03) : 160 - 169
  • [25] Expression of peroxisome proliferator-activated receptor-γ1 and peroxisome proliferator-activated receptor-γ2 in visceral and subcutaneous adipose tissue of obese women
    Giusti, V
    Verdumo, C
    Suter, M
    Gaillard, RC
    Burckhardt, P
    Pralong, F
    DIABETES, 2003, 52 (07) : 1673 - 1676
  • [26] The role of peroxisome proliferator-activated receptor-γ (PPARγ) in Alzheimer's disease
    Jiang, Qingguang
    Heneka, Michael
    Landreth, Gary E.
    CNS DRUGS, 2008, 22 (01) : 1 - 14
  • [27] Peroxisome Proliferator-Activated Receptor-α (PPARα) Expression in a Clinical Population of Pakistani Patients with Type 2 Diabetes and Dyslipidemia
    Arif, Maria
    Mondal, Tanmoy
    Majeed, Asifa
    Loffredo, Christopher A.
    Korba, Brent E.
    Ghosh, Somiranjan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [28] Retinoid X Receptor Alpha (RXRα) and Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Expression in Breast Cancer: An Immunohistochemical Study
    Ditsch, N.
    Vrekoussis, T.
    Lenhard, M.
    Ruehl, I.
    Gallwas, J.
    Weissenbacher, T.
    Friese, K.
    Mayr, D.
    Makrigiannakis, A.
    Jeschke, U.
    IN VIVO, 2012, 26 (01): : 87 - 92
  • [29] PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ (PPAR-γ) INHIBITS NADPH OXIDASE ACTIVATION UPON ISCHEMIC INSULT
    Lin, T. N.
    Wu, J. S.
    Tsai, H. D.
    Cheung, W. M.
    JOURNAL OF NEUROCHEMISTRY, 2011, 118 : 154 - 155
  • [30] Targeting Peroxisome Proliferator-Activated Receptor- ? (PPAR- ? ) to reduce paclitaxel-induced peripheral neuropathy
    Caillaud, Martial
    Patel, Nipa H.
    White, Alyssa
    Wood, Mackinsey
    Contreras, Katherine M.
    Toma, Wisam
    Alkhlaif, Yasmin
    Roberts, Jane L.
    Tran, Tammy H.
    Jackson, Asti B.
    Poklis, Justin
    Gewirtz, David A.
    Damaj, M. Imad
    BRAIN BEHAVIOR AND IMMUNITY, 2021, 93 : 172 - 185